1. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. (December 2019) Authors: Qin, Shukui; Chan, Stephen Lam; Sukeepaisarnjaroen, Wattana; Han, Guohong; Choo, Su Pin; Sriuranpong, Virote; Pan, Hongming; Yau, Thomas; Guo, Yabing; Chen, Minshan; Ren, Zhenggang; Xu, Jianming; Yen, Chia-Jui; Lin, Zhong-Zhe; Manenti, Luigi; Gu, Yi; Sun, Yongjian; Tiedt, Ralph; Hao, Lu; Song, We... Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ACTR-74. A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA. Issue 11 (6th November 2017) Authors: van den Bent, Martin; Azaro, Analia; Vos, Filip; Sepulveda, Juan; Yung, W K Alfred; Wen, Patrick; Lassman, Andrew; Joerger, Markus; Tabatabai, Ghazaleh; Rodon, Jordi; Tiedt, Ralph; Zhao, Sylvia; Kirsilae, Tiina; Vicente, Sergio; Myers, Andrea; Wick, Wolfgang Journal: Neuro-oncology Issue: Volume 19:Issue 11(2017)supplement 6 Page Start: vi16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗